Microscopic colitis is a common cause of chronic watery diarrhea. Its etiology is unknown, but use of nonsteroidal antiinflammatory drugs, aspirin, and lansoprazole may be risk factors for developing the disorder. Therapy is directed primarily at resolving the symptoms of microscopic colitis; bismuth subsalicylate, aminosalicylates, traditional corticosteroids, and budesonide have been evaluated. Compared with other therapies, budesonide has the strongest evidence for effectiveness in decreasing the volume and frequency of stools and improving the quality of life; it is, however, a costly drug. We reviewed all available primary English-language literature accounts of treatment of microscopic colitis. We performed searches of MEDLINE and International Pharmaceutical Abstracts, as well as reviewing the bibliographies from key articles, to procure pertinent reports. Microscopic colitis can be successfully treated with pharmacotherapy. Based on cost and adverse-effect profiles, antidiarrheals and bismuth subsalicylate are reasonable first options, but many patients may require budesonide to achieve remission.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1592/phco.27.3.425 | DOI Listing |
Cureus
December 2024
Internal Medicine, Wayne State University School of Medicine, Dearborn, USA.
The association between primary sclerosing cholangitis (PSC) and microscopic colitis (MC) has been explored in limited studies, suggesting potential shared pathophysiological mechanisms. This systematic review aimed to investigate this relationship by analyzing studies identified through comprehensive searches in PubMed, Embase, and the Cochrane Library. Two studies met the inclusion criteria: a case series of 12 patients and a case report, collectively analyzing 13 cases.
View Article and Find Full Text PDFArq Gastroenterol
January 2025
Universidade de Campinas, Departamento de Gastroenterologia, Campinas, SP, Brasil.
Background: Microscopic colitis (MC) is a chronic inflammatory condition of the colon, primarily characterized by watery diarrhea, with normal or near-normal endoscopic findings. It encompasses two main subtypes: lymphocytic colitis and collagenous colitis.
Objective: This position paper from the Brazilian Federation of Gastroenterology aims to review current evidence on the diagnosis and management of MC in Brazil, emphasizing the need for standardization across the country's healthcare systems.
Int J Prev Med
November 2024
Department of Pharmacology and Toxicology, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran.
J Crohns Colitis
December 2024
Division of Gastroenterology, Department of Medicine, University of Miami - Leonard Miller School of Medicine, Miami, FL, USA.
Background And Aims: The advantages of endoscopic vs histologic assessments of inflammation in inflammatory bowel disease remain unclear. We compared endoscopic and histologic inflammation in a prospective cohort. Furthermore, in patients with discordant findings, we compared the ability of endoscopy vs histology to predict disease course.
View Article and Find Full Text PDFTherap Adv Gastroenterol
December 2024
Department of Gastroenterology, Asan Medical Center, University of Ulsan College of Medicine, 88 Olympic-ro 43-gil, Songpa-gu, Seoul 05505, Republic of Korea.
Background: Immune checkpoint inhibitor (ICI)-induced colitis is a significant adverse event associated with ICI therapy, known to be linked to increased cytotoxic T-cell activity.
Objectives: To compare T-cell subsets based on the endoscopic features of ICI-induced colitis and to compare these findings with those of inflammatory bowel disease (IBD).
Design: Prospective cohort study.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!